作者:Li, Peng、Zhang, Qiang、Zheng, Hailin、Qiao, Yupu、Snyder, Gretchen L.、Martin, Terry、Yao, Wei、Zhang, Lei、Davis, Robert E.
DOI:10.1021/acs.jmedchem.4c00480
日期:——
pyridopyrroloquinoxalinone derivatives with analgesic properties. The receptor binding profiles and analgesic properties of these tetracyclic compounds were studied. Systematic optimizations of this novel scaffold culminated in the discovery of the clinical candidate, (6bR,10aS)-8-[3-(4-fluorophenoxy)propyl]-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (compound 5, ITI-333)
开发更有效且安全性更高的药物来管理和治疗多种形式的疼痛是医疗保健的关键要素。为此,我们设计并合成了一类具有镇痛特性的新型四环吡咯并喹喔啉酮衍生物。研究了这些四环化合物的受体结合特征和镇痛特性。对这种新型支架的系统优化最终发现了临床候选物 (6 bR ,10 aS )-8-[3-(4-氟苯氧基)丙基]-6 b ,7,8,9,10,10 a - hexaHydro-1 H -pyrido[3',4':4,5]pyrrolo[1,2,3- de ]quinoxalin-2(3 H )-one(化合物5 ,ITI-333),表现出有效的结合亲和力与血清素 5-HT 2A ( K i = 8.3 nM) 和 μ-阿片受体 (MOR, K i = 11 nM) 具有中等亲和力,对肾上腺素 α 1A ( K i = 28 nM) 和多巴胺 D 1 ( K i = 50) nM)受体。 ITI-333 充当